Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with…
SCHEDULE 13G/A – Description
Allogene Therapeutics, Inc.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics…
Allogene Therapeutics Announces Participation in March Investor Conference
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
SOUTH SAN FRANCISCO, Calif. , Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™…
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal…
